Division of Pulmonary Critical Care and Sleep Medicine, Department of Medicine, National Jewish Health, Denver, Colorado, USA.
Center for Genes and Environmental Health, National Jewish Health, Denver, Colorado, USA.
J Innate Immun. 2020;12(1):103-115. doi: 10.1159/000497072. Epub 2019 Mar 29.
The negative immune regulator Tollip inhibits the proinflammatory response to rhinovirus (RV) infection, a contributor to airway neutrophilic inflammation and asthma exacerbations, but the underlying molecular mechanisms are poorly understood. Tollip may inhibit IRAK1, a signaling molecule downstream of ST2, the receptor of IL-33. This study was carried out to determine whether Tollip downregulates ST2 signaling via inhibition of IRAK1, but promotes soluble ST2 (sST2) production, thereby limiting excessive IL-8 production in human airway epithelial cells during RV infection in a type 2 cytokine milieu (e.g., IL-13 and IL-33 stimulation). Tollip- and IRAK1-deficient primary human tracheobronchial epithelial (HTBE) cells and Tollip knockout (KO) HTBE cells were generated using the shRNA knockdown and CRISPR/Cas9 approaches, respectively. Cells were stimulated with IL-13, IL-33, and/or RV16. sST2, activated IRAK1, and IL-8 were measured. A Tollip KO mouse model was utilized to test if Tollip regulates the airway inflammatory response to RV infection in vivo under IL-13 and IL-33 treatment. Following IL-13, IL-33, and RV treatment, Tollip-deficient (vs. -sufficient) HTBE cells produced excessive IL-8, accompanied by decreased sST2 production but increased IRAK1 activation. IL-8 production following IL-13/IL-33/RV exposure was markedly attenuated in IRAK1-deficient HTBE cells, as well as in Tollip KO HTBE cells treated with an IRAK1 inhibitor or a recombinant sST2 protein. Tollip KO (vs. wild-type) mice developed exaggerated airway neutrophilic responses to RV in the context of IL-13 and IL-33 treatment. Collectively, these data demonstrate that Tollip restricts excessive IL-8 production in type 2 cytokine-exposed human airways during RV infection by promoting sST2 production and inhibiting IRAK1 activation. sST2 and IRAK1 may be therapeutic targets for attenuating excessive neutrophilic airway inflammation in asthma, especially during RV infection.
负向免疫调节因子 Tollip 可抑制呼吸道合胞病毒(RV)感染后的促炎反应,这是气道中性粒细胞炎症和哮喘恶化的原因之一,但其中的分子机制尚不清楚。Tollip 可能通过抑制 IRAK1 来抑制 ST2 受体(IL-33)的信号转导,后者是一种信号分子。本研究旨在确定 Tollip 是否通过抑制 IRAK1 来下调 ST2 信号,但促进可溶性 ST2(sST2)的产生,从而限制 2 型细胞因子环境(如 IL-13 和 IL-33 刺激)下人类气道上皮细胞在 RV 感染期间过度产生 IL-8。使用 shRNA 敲低和 CRISPR/Cas9 方法分别生成 Tollip 和 IRAK1 缺陷型原代人气管支气管上皮(HTBE)细胞和 Tollip 敲除(KO)HTBE 细胞。用 IL-13、IL-33 和/或 RV16 刺激细胞,测量 sST2、活化 IRAK1 和 IL-8。利用 Tollip KO 小鼠模型检测 Tollip 是否在 IL-13 和 IL-33 治疗下调节呼吸道对 RV 感染的炎症反应。在 IL-13、IL-33 和 RV 处理后,与 Tollip 充足型(vs. 缺陷型)HTBE 细胞相比,Tollip 缺陷型 HTBE 细胞产生过多的 IL-8,同时 sST2 产生减少,但 IRAK1 活化增加。在 IRAK1 缺陷型 HTBE 细胞以及用 IRAK1 抑制剂或重组 sST2 蛋白处理的 Tollip KO HTBE 细胞中,IL-13/IL-33/RV 暴露后的 IL-8 产生明显减弱。与野生型(vs. Tollip KO)小鼠相比,在 IL-13 和 IL-33 处理下,Tollip KO 小鼠对 RV 的气道中性粒细胞反应明显增强。综上所述,这些数据表明,Tollip 通过促进 sST2 的产生和抑制 IRAK1 的激活,限制 2 型细胞因子暴露的人类气道在 RV 感染期间过度产生 IL-8。sST2 和 IRAK1 可能是减轻哮喘中过度中性粒细胞气道炎症的治疗靶点,尤其是在 RV 感染期间。